Limitations, agreements, and source contact

An Open-Label Study of JZP-458 (RC-P) in Patients With Acute Lymphoblastic Leukemia (ALL)/Lymphoblastic Lymphoma (LBL) · Source last updated 2023-11-18

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement

pi Sponsor Employee

false

restrictive Agreement

false

limitations And Caveats

description

Participants in this study received JZP-458 as part of a multi-agent chemotherapeutic regimen.

point Of Contact

email

ClinicalTrialDisclosure@JazzPharma.com

organization

Jazz Pharmaceuticals

phone

215-832-3750

title

Clinical Trial Disclosure & Transparency

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice